However, within the context of holistic treatment, there was a lack of clarity regarding the relative importance of BMI as a driver of first-line therapy choice (SGLT2is versus GLP-1 RAs)
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: What is the evidence
An improvement in metabolism is often accompanied by a reduction in oxidative stress
On GLP-1 therapy, your bodys ability to signal a need for these components is dampened, making proactive supplementation essential to keep your cellular "engines" running
Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, et al
Fierce Pharma [Preprint] Samms RJ et al (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice